DTC
ACAD icon

Deep Track Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Deep Track Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000,000
Closed -$23.3M – 53
2021
Q4 		$23.3M Buy
+1,000,000
New +$20.1M 1.65% 23

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Deep Track Capital's ACAD Position: Q4 2025 in Review

Deep Track Capital sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 105,085 shares — an estimated $2.24M sold.

Deep Track Capital first reported a position in ACAD in Q2 2022 and held it in 2 quarters. The position peaked at $24.4M in Q2 2022. 335 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Deep Track Capital reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Deep Track Capital sold 105,085 Acadia Pharmaceuticals shares in Q4 2025, an estimated $2.24M.
  • Deep Track Capital first reported a position in Acadia Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Deep Track Capital's Acadia Pharmaceuticals position peaked at $24.4M in Q2 2022.
  • 335 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Deep Track Capital's 13F filing for Q4 2025, filed 13 Feb 2026.